Futu Holdings Ltd vs Zoetis Inc — how do they compare? Futu Holdings Ltd trades at $97.72 (market cap $13.94B), while Zoetis Inc trades at $77.29 (market cap $31.25B). The key difference: Zoetis Inc is far larger — about 2.2× Futu Holdings Ltd's market cap, and Zoetis Inc pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| FUTU | ZTS | |
|---|---|---|
Market Cap | $13.94B | $31.25B |
Sector | Financials | Health |
52-Week High | $199.04 | $156.76 |
52-Week Low | $89.76 | $71.91 |
Enterprise Value | $13.79B | $38.54B |
Dividend Yield | 2.62% | 2.84% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $77.13, up 4.12% in the last session, with a bearish technical signal from moving averages. The company reported strong 2025 results, including $9.47B revenue and $2.67B net income, with high profitability margins. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU. Cash flow improved to a positive $325M in 2025, though net cash flow is projected to decline in 2026.
The stock presents a mixed outlook: strong fundamentals and a consensus price target of $101.43 suggest upside, but legal risks and bearish technicals pose near-term headwinds. Earnings momentum is key, with Q2 2026 results critical after a Q1 miss. Institutional sentiment is cautious despite no sell ratings.
Trailing returns across standard periods
Latest headlines on both assets
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →